Boehringer builds out NASH pipeline with up to $870M deal with South Ko­re­a's Yuhan

Ger­many’s Boehringer In­gel­heim is ex­pand­ing its am­bi­tions in NASH, the un­treat­ed fat­ty liv­er dis­ease that has rav­aged the de­vel­oped world, cre­at­ing a lu­cra­tive tar­get that has sparked a flur­ry of drug de­vel­op­ment from bio­phar­ma firms big and small.

The com­pa­ny in 2017 joined forces with Dicer­na in a re­search and li­cens­ing deal to de­vel­op RNA in­ter­fer­ence (RNAi) ther­a­peu­tics for chron­ic liv­er dis­eases, in­clud­ing NASH. On Mon­day, Boehringer tied up with South Ko­rea’s Yuhan Corp to fight NASH in a deal worth up to $870 mil­lion — up­front and near term pay­ments of $40 mil­lion as well as po­ten­tial mile­stones pay­ments of $830 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER